SUMMARY
Despite significant progress in management of multiple myeloma (MM), prognosis of patients who fail standard treatment options is dismal. Therefore, refractory MM remains an unmet medical need. CAR-T cells are a form of cellular immunotherapy redirecting autologous T cells against tumour antigens after in vitro manufacturing. B-cell maturation antigen (BCMA) is the most promising target antigen for the development of CAR-T cell therapy for MM. In this review, we briefly go through the basics of CAR-T cell therapy applied to MM. We present the results on efficacy and safety of two recently developed CAR-T cell products: idecabtagene vicleucel (ide-cel or bb2121) and ciltacabtagene autoleucel (cilta-cel or JNJ-4528) and put them in perspective with what is published for approved CD19-CAR-T cells.
(BELG J HEMATOL 2020;12(3):128-31)
